Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insight Report 2021 - Key Players Involved are Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, & Agios Pharmaceuticals - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Relapsed or Refractory Myelodysplastic Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Relapsed or Refractory Myelodysplastic Syndrome.

Relapsed or Refractory Myelodysplastic Syndrome Emerging Drugs Chapters

This segment of the Relapsed or Refractory Myelodysplastic Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Relapsed or Refractory Myelodysplastic Syndrome Emerging Drugs

• CX-01: Cantex Pharmaceuticals

CX-01 is a new chemical entity derived from unfractionated heparin with very low anticoagulant activity. CX-01 targets key protein pathways important for AML blast cell migration to the bone marrow and retention of these cells in the marrow where they are protected from chemotherapy. CX-01 also binds with proteins involved in chemotherapy resistance and the delay in platelet recovery after chemotherapy. Together, these activities are understood to sensitize AML blasts to chemotherapy and improve clinical responses. These mechanisms of action support the potential for development in myelodysplastic syndrome, multiple myeloma, and lymphomas. Currently in phase 2 of clinical trials for the treatment of Myelodysplastic Syndrome.

• LP-108: Newave Pharmaceuticals

Mechanism of Action: Proto-oncogene protein c-bcl-2 inhibitors. The drug is in phase 1 of clinical trials for the treatment of Relapsed or Refractory Myelodysplastic Syndrome

• BTX-A51: BioTheryX

BTX-A51 appears to block a specific leukemic stem cell target (CK1-alpha) as well as super enhancer targets (CDK7/CDK9) preventing transcription of key oncogenic genes. BTX-A51 has demonstrated remarkable preclinical animal efficacy implying the eradication of AML stem cells and the potential for use in multiple malignancies. Currently in phase 1 of clinical trials for the treatment of Myelodysplastic Syndrome.

Relapsed or Refractory Myelodysplastic Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Relapsed or Refractory Myelodysplastic Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Relapsed or Refractory Myelodysplastic Syndrome

There are approx. 5+ key companies which are developing the therapies for Relapsed or Refractory Myelodysplastic Syndrome. The companies which have their Relapsed or Refractory Myelodysplastic Syndrome drug candidates in the mid to advanced stage, i.e. Phase II include, Cantex Pharmaceuticals and others.

The report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Relapsed or Refractory Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Parenteral
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Polymer
• Peptide
• Gene Therapy
• Monoclonal antibodies
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Relapsed or Refractory Myelodysplastic Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsed or Refractory Myelodysplastic Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsed or Refractory Myelodysplastic Syndrome drugs.

Relapsed or Refractory Myelodysplastic Syndrome Report Insights

• Relapsed or Refractory Myelodysplastic Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Relapsed or Refractory Myelodysplastic Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Relapsed or Refractory Myelodysplastic Syndrome drugs?
• How many Relapsed or Refractory Myelodysplastic Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Relapsed or Refractory Myelodysplastic Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Relapsed or Refractory Myelodysplastic Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Relapsed or Refractory Myelodysplastic Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Cantex Pharmaceuticals
• Novartis
• Newave Pharmaceuticals
• BioTheryX
• Agios Pharmaceuticals

Key Products

• CX-01
• BTX-A51
• Ruxolitinib
• AG-120
• LP-108

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8sr32b